Divestment

Cardior

Cardior develops RNA-based therapies for cardiovascular diseases, aiming to halt or reverse heart failure progression.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Germany
Fund: LSP 5
Entry: 2017
Exit: 2024
Website: Cardior

Cardior

Responsible Partner

Christoph Broja

Christoph Broja

Partner

News

October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

Cardior | EQT Portfolio